Scientist 2
Universal DX
Scientist 2
Universal DX
Liquid biopsy colorectal cancer detection test
About our Company:
Universal DX, Inc. is an international Company with a highly experienced team focused on cracking cancer’s code. Through our multi-omics and bioinformatics models, we have figured out how to read the disease’s signals in blood with high accuracy to detect cancer in its earliest stages. Starting with a colorectal cancer screening liquid biopsy test, we are building a multi-cancer platform that can identify the unique DNA regions associated with different types of cancers.
The Opportunity:
We are seeking a highly motivatedScientist II specializing inReagent QC Developmentto join our rapidly growing team. This role will play a critical role in developing and executing quality control (QC) methods for reagents used in our NGS-based diagnostic assays. Reporting to the Director, Reagent Development, this role will oversee reagent QC method development as well as establish reagent stability to ensure robust assay performance and compliance with regulatory standards. This role will also play an integral role in coordinating the transfer of reagent QC methods and related documentation to the Reagent Manufacturing team.
You will be part of a team that is passionate about developing novel diagnostic tests for the early detection of cancers.Aspart of the team, you will be in a Company that aims more thanto becomeone of the leaders in the industry. We want to have a huge positive impact on society by achieving the ambitious purpose of “making cancer a curable disease by detecting it earlier”.
How you’ll contribute:
Reagent QC Method Development:
Reagent Stability Studies:
Documentation and Reporting:
Cross-Functional Collaboration:
Process Optimization and Compliance:
What you’ll bring:
Required:
Preferred:
What we´ll offer:
Why Now?
This is an exciting time to be at Universal DX. We are growing rapidly and starting our US operations by building up our team, starting our lab and business operations, and establishing strategic partnerships.
We are looking for passionate changemakers to be a part of our journey in this expansive time for us.
Liquid biopsy colorectal cancer detection test
Universal Dx offers Signal-C®, a liquid biopsy test for colorectal cancer and advanced adenomas. The test analyzes a blood sample using multi-omics, computational biology, and machine learning to identify cancer signals, achieving 92% sensitivity and 94% specificity. Its collaboration with Quest Diagnostics and planned FDA approval help scale access through a major diagnostic network, differentiating it by scaled distribution and proven accuracy. The goal is to improve early detection, reduce cancer incidence and mortality, and make screening more accessible to the population.
Explore more opportunities at Universal DX